Search results for "CARDIOVASCULAR DISEASE."

showing 10 items of 2331 documents

A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin

2013

Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is as…

medicine.medical_specialtyCardiotonic AgentsHyperlipidemias030209 endocrinology & metabolismPeptide hormoneBiologyCardiovascular System03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusInsulin SecretionDrug DiscoverymedicineAnimalsHumansHypoglycemic AgentsInsulinAntiatherogenic agentHypolipidemic Agents030304 developmental biology2. Zero hungerPharmacology0303 health sciencesEvidence-Based Medicinedigestive oral and skin physiologyType 2 Diabetes MellitusLipid Metabolismmedicine.diseaseGhrelin3. Good healthEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesGastric MucosaHyperglycemiaGhrelinhormones hormone substitutes and hormone antagonistsGhrelin secretionHormoneCurrent Pharmaceutical Design
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?

2021

Prediabetes is defined as a condition of abnormal glucose metabolism, characterised by plasma glucose above normal range but not as high as required for the diagnosis of diabetes mellitus (DM). It represents a heterogeneous entity of intermediate glucose metabolism, including impaired fasting glucose, impaired glucose tolerance, and borderline glycated haemoglobin. Prediabetes is being increasingly recognised as an important metabolic state not only predisposing to a higher probability of future progression to DM, but also to an increased risk of different micro- and macrovascular complications. The recently proposed sub-phenotyping of individuals at increased risk of type 2 DM, which disti…

medicine.medical_specialtyCardiovascular disease Diabetes mellitus Kidney disease Precision medicine Prediabetes Type 2 diabetes mellitusEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyImpaired glucose tolerance03 medical and health sciencesDiabetes mellitus0302 clinical medicineDiabetes mellitusInternal medicineType 2 diabetes mellitusInternal MedicineMedicinePrediabetesDisease burdenbusiness.industryPrecision medicineType 2 Diabetes MellitusKidney diseaseCardiovascular diseasemedicine.diseaseImpaired fasting glucoseCommentarybusinessPrediabetesKidney diseaseDiabetes Therapy
researchProduct

Osteoarthritis and mortality: a prospective cohort study and systematic review with meta-analysis

2016

Objectives: Osteoarthritis (OA) is a leading cause of disability, but the relationship with premature mortality remains uncertain. We aimed to investigate the relationship between OA and mortality from any cause and from cardiovascular disease (CVD).\ud \ud Methods: Electronic literature databases searches were conducted to identify prospective studies comparing mortality in a sample of people with and without OA. Risk of all-cause and CVD mortality were summarized using adjusted hazard ratios (HRs) for joint specific (hand, hip, and knee) and joint non-specific OA. New data from the Progetto Veneto Anziani (PRO.V.A.) study were also included. Results: From the PRO.V.A. study (N 1⁄4 2927), …

medicine.medical_specialtyCardiovascular disease; Mortality; Osteoarthritis; Rheumatology; Anesthesiology and Pain MedicineOsteoarthritisDiseaseComorbidity03 medical and health sciences0302 clinical medicineRheumatologycardiovascular diseaseRisk FactorsInternal medicineOsteoarthritismedicineHumans030212 general & internal medicineProspective StudiesMortalityProspective cohort study030203 arthritis & rheumatologybusiness.industryHazard ratioOsteoarthritis Mortality Cardiovascular diseasemedicine.diseaseCardiovascular diseaseR1ComorbiditymortalityRheumatologyosteoarthritisIncreased riskAnesthesiology and Pain MedicineCardiovascular DiseasesMeta-analysisPhysical therapybusinessCardiovascular disease; Mortality; Osteoarthritis
researchProduct

Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analys…

2017

People with severe mental illness (SMI) – schizophrenia, bipolar disorder and major depressive disorder – appear at risk for cardiovascular disease (CVD), but a comprehensive meta-analysis is lacking. We conducted a large-scale meta-analysis assessing the prevalence and incidence of CVD; coronary heart disease; stroke, transient ischemic attack or cerebrovascular disease; congestive heart failure; peripheral vascular disease; and CVD-related death in SMI patients (N=3,211,768) versus controls (N=113,383,368) (92 studies). The pooled CVD prevalence in SMI patients (mean age 50 years) was 9.9% (95% CI: 7.4-13.3). Adjusting for a median of seven confounders, patients had significantly higher o…

medicine.medical_specialtyCardiovascular disease; bipolar disorder; cerebrovascular disease; congestive heart failure; coronary heart disease; major depression; premature mortality; schizophrenia; severe mental illness03 medical and health sciences0302 clinical medicinesevere mental illnessMedicineCardiovascular disease severe mental illness schizophrenia bipolar disorder major depression coronary heart disease cerebrovascular disease congestive heart failure premature mortalitycoronary heart diseasePsychiatrybipolar disorderFramingham Risk Scorebusiness.industryVascular diseaseIncidence (epidemiology)Hazard ratioCorrectionOdds ratiomedicine.diseaseCardiovascular disease030227 psychiatrycerebrovascular diseaseschizophreniaPsychiatry and Mental healthcongestive heart failurepremature mortalityHeart failureMajor depressive disorderPshychiatric Mental Healthbusinessmajor depressionBody mass index030217 neurology & neurosurgery
researchProduct

Do we need better lipid tools for cardiovascular risk assessment ?

2008

medicine.medical_specialtyCardiovascular diseases Dyslipidemia Lipoproteinsbusiness.industrymedicineGeneral MedicineIntensive care medicineRisk assessmentbusiness
researchProduct

Medical significance of peroxisome proliferator-activated receptors.

1999

Peroxisome proliferator-activated receptors (PPAR) were discovered in 1990, ending 25 years of uncertainty about the molecular mechanisms of peroxisome proliferation. Subsequently, PPARs have improved our understanding of adipocyte differentiation. But there is more to PPARs than solving a puzzle about an organelle (the peroxisome) long considered an oddity, and their medical significance goes beyond obesity too. Enhanced PPAR type alpha expression protects against cardiovascular disorders though the role of enhanced PPARgamma expression seems less favourable. PPAR mechanisms, mainly via induction of more differentiated cell phenotypes, protect against some cancers. The differentiation of m…

medicine.medical_specialtyCellular differentiationPeroxisome ProliferationPeroxisome proliferator-activated receptorReceptors Cytoplasmic and NuclearBiologyMicrobodiesInternal medicineNeoplasmsmedicineAdipocytesAnimalsHumansReceptorRegulation of gene expressionchemistry.chemical_classificationResearchFatty AcidsCell DifferentiationGeneral MedicinePeroxisomeEndocrinologychemistryNuclear receptorGene Expression RegulationCardiovascular DiseasesCancer researchPeroxisome proliferator-activated receptor alphaOxidation-ReductionTranscription FactorsLancet (London, England)
researchProduct

Evaluation of a murine single-blood-injection SAH model.

2014

The molecular pathways underlying the pathogenesis after subarachnoid haemorrhage (SAH) are poorly understood and continue to be a matter of debate. A valid murine SAH injection model is not yet available but would be the prerequisite for further transgenic studies assessing the mechanisms following SAH. Using the murine single injection model, we examined the effects of SAH on regional cerebral blood flow (rCBF) in the somatosensory (S1) and cerebellar cortex, neuro-behavioural and morphological integrity and changes in quantitative electrocorticographic and electrocardiographic parameters. Micro CT imaging verified successful blood delivery into the cisterna magna. An acute impairment of …

medicine.medical_specialtyCerebellumPathologySubarachnoid hemorrhagePhysiologyCerebral arteriesNeurophysiologylcsh:MedicineCisterna magnaSomatosensory systemInternal medicinemedicineMedicine and Health Sciencescardiovascular diseaseslcsh:ScienceElectrocorticographyBrain MappingBrain DiseasesCerebral IschemiaMultidisciplinarymedicine.diagnostic_testbusiness.industryNeurotransmissionlcsh:RBiology and Life SciencesElectroencephalographymedicine.diseasenervous system diseasesmedicine.anatomical_structureCerebral blood flowBrain ElectrophysiologyNeurologyCerebellar cortexCardiologylcsh:QbusinessResearch ArticleNeuroscienceNervous System PhysiologyPLoS ONE
researchProduct

Flegmasia cerulea dolens en paciente con carcinoma testicular

2006

Describimos un caso de flegmasia cerulea dolens secundaria a una trombosis venosa profunda por compresión de la vena cava inferior, en un varón de 31 años con un tumor germinal. Necesitó un tratamiento urgente con agentes fibrinolíticos, heparina intravenosa y quimioterapia. Con el tratamiento obtuvo una respuesta completa tumoral y una completa revascularización de la vena cava y vena femoral derecha.

medicine.medical_specialtyChemotherapybusiness.industryUrologymedicine.medical_treatmentFemoral veinFlegmasia cerulea dolensThrombolysismedicine.diseaseRevascularizationInferior vena cavaSurgeryVenous thrombosisTumor germinalmedicine.veinTrombosis venosacardiovascular systemMedicinecardiovascular diseasesRadiologybusinessGerm cell tumourTrombolisisPhlegmasia cerulea dolensActas Urológicas Españolas
researchProduct

Chronic venous insufficiency, cardiovascular disease, and mortality: a population study

2021

Abstract Aims  Evidence regarding the health burden of chronic venous insufficiency (CVI), its clinical determinants, and impact on outcome is scarce. Methods and results  Systematic phenotyping of CVI according to established CEAP (Clinical-Etiologic-Anatomic-Pathophysiologic) classification was performed in 12 423 participants (age range: 40–80 years) of the Gutenberg Health Study from April 2012 to April 2017. Prevalence was calculated age- and sex-specifically. Multivariable Poisson regression models were calculated to evaluate the relation of CVI with cardiovascular comorbidities. Survival analyses were carried out to assess the CVI-associated risk of death. Replication of findings was…

medicine.medical_specialtyChronic venous insufficiencyEpidemiologyPopulationMECHANISMSInternal medicineEpidemiologymedicineVARICOSE-VEINSeducationRISKeducation.field_of_studybusiness.industryHazard ratioWOMENChronic venous insufficiencyASSOCIATIONmedicine.diseaseCardiovascular diseaseAll-cause mortalityComorbidityPREGNANCYATHEROSCLEROSISCohortPopulation studySurgeryCardiology and Cardiovascular MedicinebusinessCohort studyEuropean Heart Journal
researchProduct